{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:39:00Z","timestamp":1790804340401,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11523-024-01102-8","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T17:02:40Z","timestamp":1730480560000},"page":"879-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-0336","authenticated-orcid":false,"given":"Erika P.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-666X","authenticated-orcid":false,"given":"Esteban Rodrigo","family":"Imedio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Ottesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh M.","family":"Mugundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza C.","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-625X","authenticated-orcid":false,"given":"Mark J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6881-8050","authenticated-orcid":false,"given":"Suzanne F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-9465","authenticated-orcid":false,"given":"David R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"4","key":"1102_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360. https:\/\/doi.org\/10.1016\/j.molcel.2015.10.040.","journal-title":"Mol Cell"},{"issue":"6","key":"1102_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.Cd-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts M, Sharpe R, Garcia-Murillas I, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2(6):524\u201339. https:\/\/doi.org\/10.1158\/2159-8290.Cd-11-0320.","journal-title":"Cancer Discov"},{"issue":"3","key":"1102_CR3","doi-asserted-by":"publisher","first-page":"20130075","DOI":"10.1098\/rsfs.2013.0075","volume":"4","author":"C G\u00e9rard","year":"2014","unstructured":"G\u00e9rard C, Goldbeter A. The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition. Interface Focus. 2014;4(3):20130075. https:\/\/doi.org\/10.1098\/rsfs.2013.0075.","journal-title":"Interface Focus"},{"key":"1102_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","volume":"188","author":"JV Forment","year":"2018","unstructured":"Forment JV, O\u2019Connor MJ. Targeting the replication stress response in cancer. Pharmacol Ther. 2018;188:155\u201367. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.005.","journal-title":"Pharmacol Ther"},{"issue":"19","key":"1102_CR5","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.4161\/cc.26062","volume":"12","author":"K Do","year":"2013","unstructured":"Do K, Doroshow JH, Kummar S. WEE1 kinase as a target for cancer therapy. Cell Cycle. 2013;12(19):3159\u201364. https:\/\/doi.org\/10.4161\/cc.26062.","journal-title":"Cell Cycle"},{"issue":"20","key":"1102_CR6","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1128\/mcb.00412-12","volume":"32","author":"H Beck","year":"2012","unstructured":"Beck H, N\u00e4hse-Kumpf V, Larsen MS, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol. 2012;32(20):4226\u201336. https:\/\/doi.org\/10.1128\/mcb.00412-12.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"1102_CR7","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.Mct-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H, Iwasawa Y, Okada M, et al. Small-molecule inhibition of WEE1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8(11):2992\u20133000. https:\/\/doi.org\/10.1158\/1535-7163.Mct-09-0463.","journal-title":"Mol Cancer Ther"},{"issue":"30","key":"1102_CR8","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1200\/jco.2014.60.4009","volume":"33","author":"K Do","year":"2015","unstructured":"Do K, Wilsker D, Ji J, et al. Phase I study of single-agent AZD1775 (MK-1775), a WEE1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33(30):3409\u201315. https:\/\/doi.org\/10.1200\/jco.2014.60.4009.","journal-title":"J Clin Oncol"},{"key":"1102_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","volume":"18","author":"TM Bauer","year":"2023","unstructured":"Bauer TM, Moore KN, Rader JS, et al. A phase Ib study assessing the safety, tolerability, and efficacy of the first-in-class Wee1 inhibitor adavosertib (AZD1775) as monotherapy in patients with advanced solid tumors. Target Oncol. 2023;18:517\u201330. https:\/\/doi.org\/10.1007\/s11523-023-00965-7.","journal-title":"Target Oncol"},{"key":"1102_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","volume":"41","author":"GS Falchook","year":"2023","unstructured":"Falchook GS, Sachdev J, Imedio ER, et al. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2023;41:493\u2013502. https:\/\/doi.org\/10.1007\/s10637-023-01371-6.","journal-title":"Invest New Drugs"},{"issue":"9","key":"1102_CR11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/jco.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu S, Yao S, Yuan Y, et al. Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clin Oncol. 2023;41(9):1725\u201334. https:\/\/doi.org\/10.1200\/jco.22.00830.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1102_CR12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/jco.20.03167","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu JF, Xiong N, Campos SM, et al. Phase II study of the Wee1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021;39(14):1531\u20139. https:\/\/doi.org\/10.1200\/jco.20.03167.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"1102_CR13","doi-asserted-by":"publisher","first-page":"abst TPS5612","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5612","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu JF, Colombo N, Oza AM, et al. ADAGIO: a Phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. J Clin Oncol. 2021;39(15 Suppl):abst TPS5612. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5612.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1102_CR14","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1021\/jm8001263","volume":"51","author":"KA Menear","year":"2008","unstructured":"Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581\u201391. https:\/\/doi.org\/10.1021\/jm8001263.","journal-title":"J Med Chem"},{"issue":"362","key":"1102_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362\u2013317. https:\/\/doi.org\/10.1126\/scitranslmed.aaf9246.","journal-title":"Sci Transl Med"},{"issue":"7035","key":"1102_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature"},{"issue":"7035","key":"1102_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"issue":"2","key":"1102_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334. https:\/\/doi.org\/10.1056\/NEJMoa0900212.","journal-title":"N Engl J Med"},{"key":"1102_CR19","unstructured":"FDA. Lynparza prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf. Accessed Apr 2024."},{"key":"1102_CR20","unstructured":"EMA. Lynparza summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf. Accessed Apr 2024."},{"issue":"20","key":"1102_CR21","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1158\/1078-0432.Ccr-17-2805","volume":"24","author":"A Lallo","year":"2018","unstructured":"Lallo A, Frese KK, Morrow CJ, et al. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res. 2018;24(20):5153\u201364. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2805.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1102_CR22","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.Ccr-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28(20):4536\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0568.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1102_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/cancers12061503","volume":"12","author":"MK Gomez","year":"2020","unstructured":"Gomez MK, Illuzzi G, Colomer C, et al. Identifying and overcoming mechanisms of PARP inhibitor resistance in homologous recombination repair-deficient and repair-proficient high grade serous ovarian cancer cells. Cancers (Basel). 2020;12(6):1503. https:\/\/doi.org\/10.3390\/cancers12061503.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1102_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023\u201331. https:\/\/doi.org\/10.1038\/nbt.2696.","journal-title":"Nat Biotechnol"},{"key":"1102_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404\u201313.","journal-title":"Biometrika"},{"key":"1102_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley JA. A confidence interval for the median survival time. Biometrics. 1982;38:29\u201341.","journal-title":"Biometrics"},{"issue":"8","key":"1102_CR27","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","volume":"25","author":"J Balmana","year":"2014","unstructured":"Balmana J, Tung NM, Isakoff SJ, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656\u201363. https:\/\/doi.org\/10.1093\/annonc\/mdu187.","journal-title":"Ann Oncol"},{"issue":"6","key":"1102_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1158\/1078-0432.Ccr-19-3470","volume":"26","author":"KA Cole","year":"2020","unstructured":"Cole KA, Pal S, Kudgus RA, et al. Phase I clinical trial of the WEE1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors: a COG Phase I consortium report (ADVL1312). Clin Cancer Res. 2020;26(6):1213\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3470.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"1102_CR29","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/jco.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo KC, Morgan MA, Sahai V, et al. Dose escalation trial of the WEE1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol. 2019;37(29):2643\u201350. https:\/\/doi.org\/10.1200\/jco.19.00730.","journal-title":"J Clin Oncol"},{"issue":"36","key":"1102_CR30","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/jco.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Pavlick AC, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34(36):4371\u201380. https:\/\/doi.org\/10.1200\/jco.2016.67.5991.","journal-title":"J Clin Oncol"},{"issue":"36","key":"1102_CR31","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/jco.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354\u201361. https:\/\/doi.org\/10.1200\/jco.2016.67.5942.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1102_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-018-0790-7","volume":"37","author":"X Lin","year":"2018","unstructured":"Lin X, Chen D, Zhang C, et al. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. J Exp Clin Cancer Res. 2018;37(1):129. https:\/\/doi.org\/10.1186\/s13046-018-0790-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"1102_CR33","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.Ccr-17-3796","volume":"24","author":"E Mendez","year":"2018","unstructured":"Mendez E, Rodriguez CP, Kao MC, et al. A Phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2018;24(12):2740\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3796.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1102_CR34","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.Ccr-11-2425","volume":"18","author":"A Rajan","year":"2012","unstructured":"Rajan A, Carter CA, Kelly RJ, et al. A Phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012;18(8):2344\u201351. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-2425.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1102_CR35","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","volume":"30","author":"J Samol","year":"2012","unstructured":"Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a Phase I study. Invest New Drugs. 2012;30(4):1493\u2013500. https:\/\/doi.org\/10.1007\/s10637-011-9682-9.","journal-title":"Invest New Drugs"},{"issue":"3","key":"1102_CR36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1349-7006.2011.02179.x","volume":"103","author":"N Yamamoto","year":"2012","unstructured":"Yamamoto N, Nokihara H, Yamada Y, et al. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012;103(3):504\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02179.x.","journal-title":"Cancer Sci"},{"issue":"15_suppl","key":"1102_CR37","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","volume":"39","author":"SN Westin","year":"2021","unstructured":"Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol. 2021;39(15_suppl):5505\u20135505. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5505.","journal-title":"J Clin Oncol"},{"key":"1102_CR38","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0959-8049(22)00822-X","volume":"174","author":"TA Yap","year":"2022","unstructured":"Yap TA, Ngoi N, Dumbrava EE, et al. NCI10329: phase Ib sequential trial of agents against DNA repair (STAR) study to investigate the sequential combination of the poly (ADP-Ribose) polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA damage response (DDR)-aberrant advanced tumors, enriched for BRCA1\/2 mutated and CCNE1 amplified cancers. Eur J Cancer. 2022;174:S7. https:\/\/doi.org\/10.1016\/S0959-8049(22)00822-X.","journal-title":"Eur J Cancer"},{"issue":"15 Suppl","key":"1102_CR39","doi-asserted-by":"publisher","first-page":"abst2562","DOI":"10.1200\/JCO.2019.37.15_suppl.2562","volume":"37","author":"MR Patel","year":"2019","unstructured":"Patel MR, Falchook GS, Wang JS-Z, et al. Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. J Clin Oncol. 2019;37(15 Suppl):abst2562. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2562.","journal-title":"J Clin Oncol"},{"key":"1102_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","volume":"174","author":"A Embaby","year":"2023","unstructured":"Embaby A, Kutzera J, Geenen JJ, et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: a biomarker-enriched phase II study. Gynecol Oncol. 2023;174:239\u201346. https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.063.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1102_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/1078-0432.Ccr-21-0158","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore KN, Chambers SK, Hamilton EP, et al. Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study. Clin Cancer Res. 2022;28(1):36\u201344. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-0158.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1102_CR42","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1200\/JCO.2022.40.16_suppl.5515","volume":"40","author":"G Au-Yeung","year":"2022","unstructured":"Au-Yeung G, Bressel M, Prall O, et al. IGNITE: a phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. J Clin Oncol. 2022;40(16):5515\u20135515. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5515.","journal-title":"J Clin Oncol"},{"issue":"10271","key":"1102_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(20)32554-x","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, Phase 2 trial. Lancet. 2021;397(10271):281\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(20)32554-x.","journal-title":"Lancet"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01102-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:07:21Z","timestamp":1731474441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01102-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"11 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA, who are codeveloping olaparib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Erika P. Hamilton: Institutional funding (AstraZeneca, Pfizer, Genentech\/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, Cascadian Therapeutics, Hutchinson MediPharma, OncoMed, MedImmune, Stem CentRx, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Millennium, TapImmune, BerGenBio, Medivation, Tesaro, Eisai, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Clovis, CytomX, InventisBio, Novartis, Silverback, Black Diamond, ArQule, Sermonix Pharmaceuticals, Sutro Biopharma, Zenith Epigenetics, Arvinas, Torque Therapeutics, Harpoon Therapeutics, Fochon Pharmaceuticals, Orinove, Molecular Templates, Unum Therapeutics, Aravive, Dana Farber Cancer Institute, G1 Therapeutics, Karyopharm Therapeutics, and Compugen) and non-financial support (Amgen, Bayer, Bristol-Myers Squibb, Genzyme, Helsinn Therapeutics, HERON, Lexicon, Medivation, Merck, Novartis, Roche, Sysmex, Guardant Health, Foundation Medicine, Deciphera, and NanoString). Gerald S. Falchook: Royalties, self (Wolters Kluwer); advisory role, institution (AbbVie, Fujifilm, Silicon, Navire, Turning Point, Predicine, Inspirna, Regeneron, Jubilant, BostonGene, Teon, Merck, Sanofi, and BridgeBio); advisory role, self (EMD Serono); speaker\u2019s honorarium for CME (Total Health Conferencing and Rocky Mountain Oncology Society); travel, self, for work and\/or research related to institution [Amgen, Bristol-Myers Squibb, EMD Serono, Fujifilm, Millennium, Sarah Cannon Research Institute (employer), and Synthorx\/Sanofi]; research funding, to institution (3-V Biosciences, Abbisko, Abbvie, ABL Bio, ADC Therapeutics, Accutar, Agenus, Aileron, American Society of Clinical Oncology, Amgen, ARMO\/Eli Lilly, Artios, AstraZeneca, Bayer, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Black Diamond, Boehringer Ingelheim, Celgene, Celldex, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, IGM Biosciences, Ignyta, Immunitas, ImmunoGen\/MacroGenics, Incyte, Jacobio, Jazz, Jounce, Jubilant, Kolltan, Loxo\/Bayer, MedImmune, Merck, Metabomed, Millennium, Mirati, miRNA Therapeutics, Molecular Templates, National Institutes of Health, Navire\/BridgeBio, NGM Bio, NiKang, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Pyramid, RasCal, Regeneron, Relay, Rgenix, Ribon, Samumed, Sapience, Seagen, Silicon, Simcha, Sirnaomics, Strategia, Syndax, Synthorx\/Sanofi, Taiho, Takeda, Tallac, Tarveda, Teneobio, Tesaro, Tocagen, Turning Point, U.T. MD Anderson Cancer Center, Vegenics, Xencor, and Zhuhai Yufan). Judy S. Wang: Consulting fees (Janssen, Stemline\/Menarini, BioNTech, and Kanaph Therapeutics); honoraria for speakers\u2019 bureau (AstraZeneca and Eisai); research funding to institution only (Syndax, AstraZeneca, Phoenix, Accutar, Celgene, BMS, Tenebio, LOXO, Nurix, Step Pharma, BioNTech, Moderna, Merck, Compugen, Boehringer Ingelheim, Kymab, Sanofi, Bicycle, Cyteir, Daiichi Sankyo, Xencor, Ribon, Klus Pharma, Artios, Genentech, Treadwell, MabSpace, IGM, Immunogen, PureTech, Erasca, Bayer, 7.8 Pharma, NGMBio, Zymeworks, Immuno-Onc, Astellas, Immunitas, Prelude, Blueprint, Beigene, Pionyr, Agenus, Adagene, Macrogenics, Jazz, StingThera, Coherus, Takeda, Taiho, Jounce, Evelo, Vedanta, Stemline, GSK, Janssen, Black Diamond, Vigeo, Relay, and Jacobio). Siqing Fu: Clinical trial research support\/grant funding, institution {National Institutes of Health [NIH]\/National Cancer Institute [NCI] P30CA016672 \u2013 Core Grant [Cancer Center Support Grant (CCSG) Shared Resources]; Abbisko; BeiGene; BioAtla, LLC.; Boehringer Ingelheim; CUE Biopharma, Inc.; Eli Lilly & Co.; Exelisis; Greenfire Bio, Inc.; Hookipa Biotech; IMV, Inc.; Innovent Biologics, Co., Ltd.; K-Group Beta; Lyvgen Biopharm, Co., Ltd.; MacroGenics; MediLink Therapeutics, Co. Ltd.; Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; NextCure, Inc.; Ningbo NewBay Technology Development Co., Ltd.; Novartis; NovoCure; Nykode Therapeutics AS.; Parexel International, LLC; Pionyr Immunotherapeutics, Inc.; PureTech Health, LLC; Sellas Life Sciences Group; Soricimed Biopharma, Inc.; SQZ Biotechnologies; Sumitomo Dainippon; Taiho Oncology and NCCN; Treadwell Therapeutics; Turnstone Biologics; Tyligand Bioscience, Ltd.; and Virogin Biotech, Ltd}. Amit M. Oza: principal investigator (PI) and steering committees (AstraZeneca, GSK, and Clovis); advisory boards (AstraZeneca, Morphosys); CEO [Ozmosis Research (uncompensated)], institutional support for clinical trials (AstraZeneca, GSK, Esperas Pharm, Clovis, Karyopharm, Ocellaris, Senhwa, Merck, ImmunoGen, Immunovaccine, Pfizer, Aravive, Mersana, Seagen, Alkermes, Verastem, Zentalis, Shuttck Labs, Sutro, NovoCure, Plexxikon, and Amgen). Esteban Rodrigo Imedio: Former employee (AstraZeneca). Sanjeev Kumar: Employee and stock ownership (AstraZeneca). Lone Ottesen: Former employee and stock ownership (AstraZeneca). Ganesh M. Mugundu: Former employee and stock ownership (AstraZeneca). Elza C. de Bruin: Employee and stock ownership (AstraZeneca). Mark J. O\u2019Connor: Employee and stock ownership (AstraZeneca). Suzanne F. Jones: Consulting\/advisory role (Amgen) \u2013 all payments to institution; stock ownership (HCA Healthcare). David R. Spigel: Institutional funding (AstraZeneca, Genentech\/Roche, Novartis, Celgene, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Abbvie, Foundation Medicine, GlaxoSmithKline, Lilly, Merck, Moderna Therapeutics, Nektar, Takeda, Amgen, University of Texas Southwestern Medical Center \u2013 Simmons Cancer Center, G1 Therapeutics, Neon Therapeutics, Celldex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Acerta Pharma, Oncogenex, Astellas Pharma, GRAIL, Transgene, Aeglea Biotherapeutics, Tesaro, Ipsen, ARMO BioSciences, and Millennium); consultation (AstraZeneca, TRM Oncology, Precision Oncology, Evelo Therapeutics, Illumina, PharmaMar, Genentech\/Roche, Novartis, Celgene, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Abbvie, Foundation Medicine, GlaxoSmithKline, Lilly, and Merck); travel and expenses (AstraZeneca, Genzyme, Intuitive Surgical, Purdue Pharma, Spectrum Pharmaceuticals, Sysmex, EMD Serono, Genentech\/Roche, Novartis, Celgene, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Abbvie, Foundation Medicine, GlaxoSmithKline, Lilly, and Merck). Bob T. Li: Uncompensated advisor and consultant (Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, and Lilly); research grants, institution (Amgen, AstraZeneca, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Hengrui USA, and Lilly); academic travel support (Jiangsu Hengrui Medicine and MORE Health); inventor on two institutional patents at MSK (US62\/685,057 and US62\/514,661); intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Potential Conflicts of Interests"}},{"value":"The institutional review boards of all participating sites approved the study, all patients provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at . Data for studies directly listed on Vivli can be requested through Vivli at . Data for studies not listed on Vivli could be requested through Vivli at . AstraZeneca Vivli member page is also available outlining further details: .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Writing \u2013 original draft; writing \u2013 review and editing: E.P. Hamilton, G.S. Falchook, J.S. Wang, S. Fu, A.M. Oza, E.R. Imedio, S. Kumar, L. Ottesen, G.M. Mugundu, E.\u00a0de\u00a0Bruin, M. J. O\u2019Connor, S.F. Jones, D.R. Spigel, and B.T. Li. Investigation: E.P. Hamilton, G.S. Falchook, J.S. Wang, S. Fu, A.M. Oza, and B.T. Li. Methodology: E.R. Imedio, S. Kumar, G.M. Mugundu, S.F. Jones, and D.R. Spigel. Conceptualization: E.R. Imedio, S. Kumar, G.M. Mugundu, M. J. O\u2019Connor, S.F. Jones, and D.R. Spigel. Supervision: E.R. Imedio, S. Kumar, and G.M. Mugundu. Project administration: E.R. Imedio, S. Kumar, and G.M. Mugundu.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}